Aspen Pharmacare Holdings (FRA:LDZA) Cash-to-Debt : 0.34 (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Aspen Pharmacare Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aspen Pharmacare Holdings's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.34.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Aspen Pharmacare Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Aspen Pharmacare Holdings's Cash-to-Debt or its related term are showing as below:

FRA:LDZA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 0.24 Max: 0.37
Current: 0.34

During the past 13 years, Aspen Pharmacare Holdings's highest Cash to Debt Ratio was 0.37. The lowest was 0.17. And the median was 0.24.

FRA:LDZA's Cash-to-Debt is ranked worse than
67.09% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs FRA:LDZA: 0.34

Aspen Pharmacare Holdings Cash-to-Debt Historical Data

The historical data trend for Aspen Pharmacare Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aspen Pharmacare Holdings Cash-to-Debt Chart

Aspen Pharmacare Holdings Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash-to-Debt

Get a 7-Day Free Trial

0.17

0.34

0.28

0.37

0.34

Aspen Pharmacare Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															0.28	0.30	0.37	0.32	0.34

Competitive Comparison of Aspen Pharmacare Holdings's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspen Pharmacare Holdings's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aspen Pharmacare Holdings's Cash-to-Debt falls into.

Aspen Pharmacare Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aspen Pharmacare Holdings's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	621.901	/	(570.332	+	1267.393)
	=	0.34

Aspen Pharmacare Holdings's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	621.901	/	(570.332	+	1267.393)
	=	0.34

Aspen Pharmacare Holdings (FRA:LDZA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aspen Pharmacare Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aspen Pharmacare Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspen Pharmacare Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aspen Pharmacare Holdings Ltd (FRA:LDZA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

APN:South Africa APNHY:USA

Address

Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF

Website

https://www.aspenpharma.com

Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) - this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin - this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.

Aspen Pharmacare Holdings Headlines

No Headlines